QL-RT-10

Overview

Retatrutide (LY3437943) is a next-generation incretin-based research compound. It functions as a simultaneous agonist at three receptors: GLP-1, GIP, and glucagon receptors -- making it the first of the 'triple G' class to reach late-stage clinical research. Unlike tirzepatide (dual GIP/GLP-1) or semaglutide (single GLP-1), retatrutide's glucagon receptor activity adds a third mechanistic dimension studied for its role in hepatic lipid oxidation, glycogenolysis, and basal metabolic rate modulation. Early clinical data showed unprecedented efficacy endpoints, generating significant research interest in multi-receptor incretin pharmacology.

Primary Research Areas

• Triple receptor agonism -- GIP/GLP-1/Glucagon concurrent activation, receptor occupancy profiling, and three-way signaling crosstalk characterization
• Adipose tissue metabolism -- multi-pathway lipid regulation, energy expenditure modulation, and brown adipose tissue activation studies
• Metabolic rate research -- glucagon-mediated basal metabolic rate enhancement and thermogenic effects distinct from GLP-1/GIP pathways
• Hepatic lipid studies -- liver fat reduction mechanisms, hepatic lipid oxidation, and NAFLD/NASH model applications
• GLP-1 + GIP + Glucagon signaling -- novel receptor crosstalk research and comparative studies against dual and single agonists
• Dose-response characterization -- titration studies across the three receptor systems at varying molar ratios